OptimizeRx inks option to buy back shares from Vicis for $9 million

Agreement also includes derivative securities, will expire Dec. 31

By Devika Patel

Knoxville, Tenn., Jan. 11 - OptimizeRx Corp. negotiated an option to repurchase all of its shares and derivative securities held by Vicis Capital Master Fund on Jan. 10, according to an 8-K filed Friday with the Securities and Exchange Commission. The securities will be bought for $9 million, and the option expires on Dec. 31.

The shares and securities include series A convertible preferred stock, series B convertible preferred stock, common stock and warrants to purchase preferreds.

Based in Rochester, Mich., OptimizeRx provides platforms to help patients better afford and comply with their medicines and health-care products, while offering pharmaceutical and health-care companies ways to expand patient awareness, access and adherence to their brands.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.